Apellis Pharmaceuticals Highlights Q2 2025 Achievements
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) proudly announced its financial results for the second quarter of 2025, showcasing significant achievements and growth trajectories. With an unwavering commitment to developing innovative treatments for complex diseases, Apellis continues to press forward in complement science.
Key Financial Figures for the Quarter
In the second quarter of 2025, Apellis generated impressive revenues of $178 million, including a remarkable $171 million from U.S. net product sales. This performance reflects the ongoing robust demand for their flagship products, primarily driven by the growing market for SYFOVRE and EMPAVELI.
Sustained Growth in Product Demand
SYFOVRE (pegcetacoplan injection), designed to address geographic atrophy secondary to age-related macular degeneration, saw a quarter-over-quarter increase of 6% in demand. This translates into U.S. net product revenue of $151 million in Q2 2025, solidifying SYFOVRE's position as the market leader in its category.
Strategic Partnerships and Revenue Opportunities
In an exciting development, Apellis entered into a capped royalty purchase agreement with Sobi, where the company stands to receive up to $300 million for 90% of ex-U.S. royalties of Aspaveli. This partnership is expected to enhance Apellis's revenue streams significantly and support sustained business growth.
Advancements with EMPAVELI
EMPAVELI has also set a high bar following its recent U.S. FDA approval to treat patients aged 12 years and older suffering from C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). This approval builds upon the success seen in the Phase 3 VALIANT study, highlighting a 68% reduction in proteinuria, offering new hope to patients affected by these rare and severe conditions.
Future Endeavors in Rare Kidney Diseases
Apellis is poised to initiate pivotal studies for EMPAVELI in two significant areas—Delayed graft function (DGF) and Focal segmental glomerulosclerosis (FSGS)—where no approved therapies currently exist. This promising direction reflects Apellis's dedication to expanding access to transformative therapies.
Organizational Updates and Leadership
As part of its ongoing growth, Apellis has made key organizational appointments. Leslie Meltzer, Ph.D., has been named the chief research and development officer, bringing valuable experience in biopharmaceutical leadership. Kelley Boucher also joined as the chief people officer, adding depth to the talent management and human resources strategies of the company.
Financial Outlook and Operations
As of June 30, 2025, Apellis reported cash and cash equivalents of $370 million, positioning the company favorably to reach sustainable profitability. The financial outlook is bright, bolstered by anticipated revenues from existing products and the partnership with Sobi.
Frequently Asked Questions
What were the key financial results for Apellis Pharmaceuticals in Q2 2025?
Apellis reported revenues of $178 million, significantly driven by $171 million from U.S. net product sales.
What products contributed most to the revenue growth?
The primary contributors to revenue were SYFOVRE and EMPAVELI, with SYFOVRE generating $151 million in U.S. net product revenues for the quarter.
What recent FDA approvals did Apellis receive?
Apellis received FDA approval for EMPAVELI, allowing treatment for patients with C3G and primary IC-MPGN.
Can you explain the partnership with Sobi?
Under the capped royalty purchase agreement, Apellis will receive up to $300 million for 90% of ex-U.S. royalties of Aspaveli, which is expected to enhance revenue streams.
What is the cash position of Apellis Pharmaceuticals?
As of June 30, 2025, Apellis had $370 million in cash and cash equivalents, poised for future growth and sustainable profitability.
